Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vertex Pharmaceuticals Inc VRTX

Healthcare Biotechnology
Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on investing in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has four approved medicines that treat the underlying cause of cystic fibrosis (CF), and one approved therapy that treats severe sickle cell disease (SCD) and... see more

Recent & Breaking News (NDAQ:VRTX)

Morning Research on Amgen, Affymax, Vertex Pharma, Questcor Pharma, and Repros Therapeutics

PR Newswire April 1, 2013

FDA's New "Breakthrough" Designation Allows New Drugs to Gain Approval After Just 1 Round of Testing

Marketwired March 7, 2013

VX-787 Showed Significant Antiviral Activity and Reduced the Severity and Duration of Influenza Symptoms in Phase 2 Challenge Study

Business Wire March 4, 2013

Vertex Announces Webcasts of its Presentations at Two Investor Conferences

Business Wire February 27, 2013

Vertex Announces Initiation of Pivotal Phase 3 Program of VX-809 in Combination with Ivacaftor for the Treatment of People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation

Business Wire February 26, 2013

Republic of Ireland Approves Funding for KALYDECO(tm) (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis, for People with a Specific Genetic Mutation (G551D)

Business Wire February 1, 2013

FDA Approved a Total of 39 New Drugs in 2012 -- Fifteen Year High

Marketwired February 1, 2013

The Real Story Behind RIG, CMI, VRTX and TSO

Marketwired February 1, 2013

Free Research Reports on ADT, CHK, MTOR and VRTX Issued by the Bedford Report

Marketwired January 31, 2013

Vertex Reports Full-Year and Fourth Quarter 2012 Financial Results and Provides Updates on Key Development Programs

Business Wire January 29, 2013

Free Research Reports on RSYS, SNTS, VPHM and VRTX Issued by the Bedford Report

Marketwired January 16, 2013

Vertex to Report Fourth Quarter and Full Year 2012 Financial Results on Tuesday, January 29

Business Wire January 15, 2013

Vertex Outlines Corporate Strategy and Defines Key 2013 Business Priorities

Business Wire January 6, 2013

Should Recent Insider Selling on VRTX, DOV, MWV and PBY Matter to You?

Marketwired December 21, 2012